Vestmark Advisory Solutions Inc. Acquires 321,894 Shares of 10x Genomics $TXG

Vestmark Advisory Solutions Inc. boosted its holdings in 10x Genomics (NASDAQ:TXG) by 109.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 615,294 shares of the company’s stock after purchasing an additional 321,894 shares during the period. Vestmark Advisory Solutions Inc. owned approximately 0.50% of 10x Genomics worth $7,125,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TXG. Savant Capital LLC increased its holdings in shares of 10x Genomics by 441.6% in the second quarter. Savant Capital LLC now owns 162,771 shares of the company’s stock worth $1,885,000 after buying an additional 132,719 shares during the period. Bank of Montreal Can boosted its holdings in 10x Genomics by 4,787.2% during the 2nd quarter. Bank of Montreal Can now owns 588,080 shares of the company’s stock valued at $6,810,000 after acquiring an additional 576,047 shares during the period. Versor Investments LP bought a new position in 10x Genomics during the 2nd quarter worth approximately $256,000. Simon Quick Advisors LLC bought a new position in 10x Genomics during the 2nd quarter worth approximately $428,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in 10x Genomics by 176.8% in the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 289,269 shares of the company’s stock worth $3,350,000 after purchasing an additional 184,757 shares during the period. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,149 shares of company stock worth $539,865 in the last quarter. 9.39% of the stock is owned by company insiders.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $15.25 on Friday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $17.25. The stock has a market capitalization of $1.90 billion, a P/E ratio of -24.60 and a beta of 2.13. The company’s 50-day moving average is $12.81 and its 200 day moving average is $11.74.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The business had revenue of $149.00 million during the quarter, compared to analyst estimates of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.71%. 10x Genomics’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business posted ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. Research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Canaccord Genuity Group increased their price objective on 10x Genomics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. upped their price target on shares of 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Friday. Morgan Stanley cut their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Finally, Barclays increased their target price on shares of 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $14.58.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.